PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24108197-9	2014	CONCLUSIONS: The data suggest that the 111In-DOTA-minigastrin analogues studied are promising candidates for the scintigraphy of CCK-2 receptor-expressing tumours; 111In-DOTA-MG47 and 111In-DOTA-MG11 are the most promising.	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	45-49	cholecystokinin B receptor	Rattus norvegicus	129-143	
34208516-1	2021	The new minigastrin analog DOTA-MGS5 is a promising new candidate for targeting cholecystokinin-2 receptor (CCK2R)-expressing tumors.	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	27-31	cholecystokinin B receptor	Rattus norvegicus	80-106	
34208516-1	2021	The new minigastrin analog DOTA-MGS5 is a promising new candidate for targeting cholecystokinin-2 receptor (CCK2R)-expressing tumors.	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid	27-31	cholecystokinin B receptor	Rattus norvegicus	108-113